M&A / Deals Roche and C4 Therapeutics to advance degrader-antibody conjugates research Pharmaceutical TechnologyRoche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer.M&A / DealsOncologyRead full story pharminent April 10, 2026 (Last updated: April 10, 2026) Pharmaceutical Technology Roche has signed a new collaboration deal with C4 Therapeutics to jointly advance DACs research to introduce a new therapeutic modality for cancer. M&A / DealsOncologyRead full story Post navigation Previous: Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisationNext: Roche places a $1bn bet on C4T degrader-antibody conjugates Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
